WallStreetZenWallStreetZen

NASDAQ: VTVT
Vtv Therapeutics Inc Stock

$18.83+0.00 (+0%)
Updated Jun 24, 2024
VTVT Price
$18.83
Fair Value Price
$4.28
Market Cap
$56.68M
52 Week Low
$7.38
52 Week High
$31.79
P/E
-2.22x
P/B
2.73x
P/S
70.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.00M
Earnings
-$20.62M
Gross Margin
100%
Operating Margin
-2,050.3%
Profit Margin
-2,061.6%
Debt to Equity
1.36
Operating Cash Flow
-$21M
Beta
0.7
Next Earnings
Aug 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VTVT Overview

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VTVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VTVT ($18.83) is overvalued by 340.28% relative to our estimate of its Fair Value price of $4.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VTVT ($18.83) is not significantly undervalued (340.28%) relative to our estimate of its Fair Value price of $4.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VTVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VTVT due diligence checks available for Premium users.

Be the first to know about important VTVT news, forecast changes, insider trades & much more!

VTVT News

Valuation

VTVT fair value

Fair Value of VTVT stock based on Discounted Cash Flow (DCF)
Price
$18.83
Fair Value
$4.28
Overvalued by
340.28%
VTVT ($18.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VTVT ($18.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VTVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VTVT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.22x
Industry
-6.96x
Market
30.03x

VTVT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.73x
Industry
6.29x
VTVT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VTVT's financial health

Profit margin

Revenue
$1.0M
Net Income
-$4.9M
Profit Margin
-486.5%
VTVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VTVT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$54.2M
Liabilities
$28.2M
Debt to equity
1.36
VTVT's short-term assets ($53.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTVT's short-term assets ($53.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTVT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VTVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.3M
Investing
$0.0
Financing
$50.1M
VTVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VTVT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VTVT$56.68M0.00%-2.22x2.73x
CALC$56.43M-1.87%-2.44x3.27x
PASG$56.09M0.00%-0.59x0.53x
OVID$56.05M+1.28%-1.08x0.72x
AKTX$58.00M-1.35%N/A-16.32x

Vtv Therapeutics Stock FAQ

What is Vtv Therapeutics's quote symbol?

(NASDAQ: VTVT) Vtv Therapeutics trades on the NASDAQ under the ticker symbol VTVT. Vtv Therapeutics stock quotes can also be displayed as NASDAQ: VTVT.

If you're new to stock investing, here's how to buy Vtv Therapeutics stock.

What is the 52 week high and low for Vtv Therapeutics (NASDAQ: VTVT)?

(NASDAQ: VTVT) Vtv Therapeutics's 52-week high was $31.79, and its 52-week low was $7.38. It is currently -40.77% from its 52-week high and 155.15% from its 52-week low.

How much is Vtv Therapeutics stock worth today?

(NASDAQ: VTVT) Vtv Therapeutics currently has 3,010,206 outstanding shares. With Vtv Therapeutics stock trading at $18.83 per share, the total value of Vtv Therapeutics stock (market capitalization) is $56.68M.

Vtv Therapeutics stock was originally listed at a price of $435.60 in Jul 30, 2015. If you had invested in Vtv Therapeutics stock at $435.60, your return over the last 8 years would have been -95.68%, for an annualized return of -32.47% (not including any dividends or dividend reinvestments).

How much is Vtv Therapeutics's stock price per share?

(NASDAQ: VTVT) Vtv Therapeutics stock price per share is $18.83 today (as of Jun 24, 2024).

What is Vtv Therapeutics's Market Cap?

(NASDAQ: VTVT) Vtv Therapeutics's market cap is $56.68M, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vtv Therapeutics's market cap is calculated by multiplying VTVT's current stock price of $18.83 by VTVT's total outstanding shares of 3,010,206.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.